Abstract The Clinical Practice Manual for Hepatocellular Carcinoma was published based
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …

Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end
of the tunnel? - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Background & Aims Programmed cell death-1 (PD-1) inhibitor treatment can cause
hyperprogressive disease (HPD), but the incidence, outcome, and predictive factors of HPD …

Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment
of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as …

The results of the Phase 3 HIMALAYA trial were presented at ASCO-GI 2022 (1).
Durvalumab+ tremelimumab (Durva/Treme) has also been approved for the treatment of …

Upfront systemic therapy with subsequent locoregional therapy is a new therapeutic option
for intermediate-stage hepatocellular carcinoma (HCC). The first example of such treatment …

Purpose: This study aimed to investigate the biomarkers of sintilimab (anti–PD-1) plus
IBI305 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma (HCC), as well as …

Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been
developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function …

Abstract Background & Aims In patients with unresectable hepatocellular carcinoma (HCC),
the combination of atezolizumab and bevacizumab improved progression‐free survival …

Immune-checkpoint inhibitor-based combination immunotherapy has become a first-line
treatment for several major types of cancer including hepatocellular carcinoma (HCC), renal …